Protagonist Therapeutics PTGX Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Protagonist Therapeutics’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's free cash flow yield?
- Protagonist Therapeutics (PTGX) reported free cash flow yield of -12.1% in Q3 2023.
- How has Protagonist Therapeutics's free cash flow yield changed year-over-year?
- Protagonist Therapeutics's free cash flow yield increased by 52.0% year-over-year, from -25.2% to -12.1%.
- What is the long-term trend for Protagonist Therapeutics's free cash flow yield?
- Over 2 years (2020 to 2022), Protagonist Therapeutics's free cash flow yield has grown at a 63.6% compound annual growth rate (CAGR), from -7.6% to -20.3%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.